FDA Accepts Genentech's SBLA For Lunsumio-Polivy In LBCL; Decision Slated For February 2027

Genentech said the FDA has accepted its supplemental BLA for Lunsumio VELO as a subcutaneous formulation in combination with Polivy for adult patients. The filing acceptance is a positive regulatory step, but it is not an approval and no clinical or commercial data were disclosed. The news is modestly supportive for Roche/Genentech shares, with limited near-term market impact absent further FDA action.

Analysis

Genentech said the FDA has accepted its supplemental BLA for Lunsumio VELO as a subcutaneous formulation in combination with Polivy for adult patients. The filing acceptance is a positive regulatory step, but it is not an approval and no clinical or commercial data were disclosed. The news is modestly supportive for Roche/Genentech shares, with limited near-term market impact absent further FDA action.